HLS Therapeutics Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- HLS Therapeutics's estimated annual revenue is currently $15.9M per year.
- HLS Therapeutics received $125.0M in venture funding in September 2018.
- HLS Therapeutics's estimated revenue per employee is $201,000
- HLS Therapeutics's total funding is $155M.
- HLS Therapeutics has 79 Employees.
- HLS Therapeutics grew their employee count by 52% last year.
- HLS Therapeutics currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Fresenius Kabi ...||$27.3M||136||21%||N/A|
|Dalton Pharma S...||$31.6M||157||5%||N/A|
What Is HLS Therapeutics?
The Heritage of Life Sciences Products HLS Therapeutics is about maintaining the heritage of life science products. We are dedicated to keeping trusted branded drugs on the market. HLS provides access to medications critical to Health Care Providers, patients and their caregivers with the high-quality brand names they trust. Who We Are HLS Therapeutics Inc. is a specialty pharmaceutical company dedicating itself to acquiring and distributing commercial stage mature, or legacy, branded pharmaceutical drugs for the North American markets. Our management team is comprised of seasoned pharmaceutical executives with a strong track record of success. Building on the expertise of our founders, HLS is focused on treatment products for the central nervous system, soon to be followed by specialty products in other therapeutic areas. HLS Therapeutics focuses on the North American market and has operational locations in Toronto (Etobicoke, Ontario), and Philadelphia (Rosemont, Pennsylvania), We source our products from the drug's originator or from best-in-class manufacturing partners, ensuring our brands are manufactured with the highest standards of quality and in compliance with FDA and Health Canada's regulations. Our Goal/Our Mission HLS is dedicated to the stewardship of branded pharmaceuticals through their life cycle during and post exclusivity, providing access to treatments critical to Health Care Providers, patients and their caregivers with the brand names they trust.keywords:N/A
Number of Employees
Employee Growth %
|Alec Wilson||Brand Manager Clozaril||Email Available|
|Hemanth Varghese||Head Of Corporate Strategy & Business Development||Email Available|
|Elizabeth Fry||Manager, Therapeutic Area Development||Email Available|
|Ryan Lennox||General Counsel||Email Available|
|David Iwanicki||Director Of National Accounts And Rsap Program||Email Available|
|Greg Gubitz||Chief Executive Officer||Email Available|
|Gilbert Godin||President and Chief Operating Officer||Email Available|
|Tim Hendrickson||Chief Financial Officer||Email Available|
|Hemanth Varghese||Head of Corporate Strategy and Business Development|
|sanjiv Sharma||Chief Commercial Officer||Email Available|
HLS Therapeutics News
HLS Therapeutics Inc. (TSE:HLS) shareholders might be concerned after seeing the share price drop 18% in the last month. But looking back ...
HLS Therapeutics has only been paying a dividend for a year or so, so investors might be curious about its 1.4% yield.” Before you buy any ...
HLS Therapeutics Inc. (TSX:HLS) has a current EV or Enterprise Value of 457566. The EV displays how the market assigns value to a firm as a ...
HLS Therapeutics Funding
|2018-09-13||$125.0M||Undisclosed||Silicon Valley Bank||Article|